New combo therapy shows promise for tough esophageal cancer

NCT ID NCT05357846

First seen May 04, 2026 · Last updated May 14, 2026 · Updated 1 time

Summary

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation before surgery helps people with a certain type of esophageal cancer live longer. About 422 adults with stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal cancer who have not had prior treatment will be randomly assigned to receive either the new combination or standard treatment alone. The main goal is to see if the combination improves overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.